Flu season helps CSL lift profit guidance

May 18, 2018

Vaccine supplier CSL has lifted its full-year profit after the northern hemisphere flu season.

CSL has lifted its full-year profit guidance thanks to strong sales of products including its Seqirus flu vaccine in the northern hemisphere.

The vaccines and blood products supplier says sales of drugs to treat haemophilia and angiodema - a hereditary condition that can cause swelling of the face, abdomen and limbs - were stronger than expected and that it now expects net profit of between $US1.68 billion and $US1.71 billion on a constant currency basis.

That is as much as 28 per cent higher than the $US1.34 billion reported for the last financial year, and compares to previous guidance of $US1.55 billion to $US1.60 billion.

More in National
Login Sign Up

Dummy text